Nikkei ends near 29-1/2-year high on vaccine, stimulus hopes


Japanese stocks got off to a bright start after Moderna Inc said it had applied for U.S. emergency authorization for its COVID-19 vaccine. Moderna's candidate is the second vaccine likely to win U.S. approval for a potential rollout this year.

TOKYO: Japan's benchmark Nikkei closed near a 29-1/2-year high on Tuesday, tracking gains in U.S. stock futures over growing optimism that major drugmakers will roll out coronavirus vaccines before year-end.

The Nikkei 225 index ended up 1.34% at 26,787.54, near its highest level since April 1991, hit earlier in the session. The broader Topix rose 0.77% to 1,768.38.

Securities brokerages, non-ferrous metals and metal products led the advance on the main bourse.

Japanese stocks got off to a bright start after Moderna Inc said it had applied for U.S. emergency authorization for its COVID-19 vaccine. Moderna's candidate is the second vaccine likely to win U.S. approval for a potential rollout this year.

In addition, Japan's government has vowed to compile a stimulus package to help the economy mitigate short-term economic impacts from a recent rise in coronavirus infections.

"There may be some slight adjustments, but Japanese stocks won't fall very far," said Kiyoshi Ishigane, chief fund manager at Mitsubishi UFJ Kokusai Asset Management Co.

"Approval of a vaccine is a big boost. Some traders are also focused on an increase in Japanese fiscal spending."

Gains in U.S. stock futures, up more than 0.8% in Asian trade, and strong Chinese factory activity data also bolstered Japanese shares.

The stocks that gained the most among the top 30 core Topix names were Fanuc Corp, up 3.09%, and Shin-Etsu Chemical Co Ltd, up 2.8%.

The underperformers among the Topix 30 were Nintendo Co Ltd, down 3.19%, and Recruit Holdings Co Ltd, which lost 2.89%.

There were 193 advancers on the Nikkei index against 30 decliners.

The volume of shares traded on the Tokyo Stock Exchange's main board was 1.33 billion, compared to the average of 1.27 billion in the past 30 days. - Reuters

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 18
Cxense type: free
User access status: 3

Nikkei 225 index , vaccines , Covid-19

   

Did you find this article insightful?

Yes
No

Next In Business News

Morgan Stanley CEO's annual pay rises by over 20%
‘Unstoppable’ luxury stocks remind some investors of US tech
Ambani’s Reliance doubles down on 5G pledge after record profit
PUNB offers payment deferment, rental discount
CPO futures may undergo technical correction next week
Blackstone-backed Patria eyes expansion in Latam, Asia
METALS: Tin, aluminium, copper prices down
Oil price falls on China's COVID-19 cases, high crude build
IBM, Intel slump weighs on Wall St as coronavirus concerns rise
GLOBAL MARKETS-Weak data, earnings drag stocks lower

Stories You'll Enjoy